Menü
Microsoft selbst warnt vor der Verwendung von Internet Explorer, da er nicht mehr den neuesten Web- und Sicherheitsstandards entspricht. Wir können daher nicht garantieren, dass die Seite im Internet Explorer in vollem Umfang funktioniert. Nutze bitte Chrome oder Firefox.

News und Analysen

2 Risky Dividend Stocks to Avoid: https://g.foolcdn.com/editorial/images/727745/high-risk-risky-danger-investing-mistakes-penny-stocks-margin.jpg
2 Risky Dividend Stocks to Avoid

It can be tempting to invest in a dividend stock for its ultra-high yield. But often, an excessive dividend yield is a sign that all is not well.

Elevated inflation and rising interest rates are

Roku Is Down 87% From Its High. Time to Buy?: https://g.foolcdn.com/editorial/images/727717/pointing-remote-to-tv.jpg
Roku Is Down 87% From Its High. Time to Buy?

After hitting the public markets in September 2017, Roku (NASDAQ: ROKU) shares skyrocketed more than 1,900% in a period of less than four years. This business benefited from loose monetary policy, a

Form 8.3 - The Vanguard Group, Inc.: Horizon Therapeutics plc: https://mms.businesswire.com/media/20210505005534/en/876086/5/5009664_Horizon_Logo_Full-Color_CMYK_M01_%281%29.jpg
Form 8.3 - The Vanguard Group, Inc.: Horizon Therapeutics plc
Form 8.3 - The Vanguard Group, Inc.: Horizon Therapeutics plc
Why Shares of TG Therapeutics Soared on Tuesday: https://g.foolcdn.com/editorial/images/727875/physician-going-over-results-with-patient-1.jpg
Why Shares of TG Therapeutics Soared on Tuesday

Shares of TG Therapeutics (NASDAQ: TGTX) were up by 18% as of mid-afternoon Tuesday after reports that the biotech's multiple sclerosis therapy Briumvi would have better-than-expected sales in its

Could Moderna Become a Warren Buffett Stock?: https://g.foolcdn.com/editorial/images/727526/buffett11-tmf.jpg
Could Moderna Become a Warren Buffett Stock?

Moderna (NASDAQ: MRNA) is a growth stock that's had plenty of time in the limelight, but that doesn't mean it'd fit the exacting specifications of Warren Buffett. Berkshire Hathaway's portfolio

1 Magnificent Growth Stock With 840% Upside, According to Wall Street: https://g.foolcdn.com/editorial/images/727604/growth-5.jpg
1 Magnificent Growth Stock With 840% Upside, According to Wall Street

Ark Invest CEO Cathie Wood has been relentlessly optimistic throughout the Nasdaq Composite bear market. Her flagship Ark Innovation ETF is currently down 75% off its high, but she still expects the

Want to Travel in Your Retirement? 4 Moves to Make in Your 20s.: https://g.foolcdn.com/editorial/images/727692/private-jet-plan-travel-business-vacation.jpg
Want to Travel in Your Retirement? 4 Moves to Make in Your 20s.

People love to travel. Whether it's trying to climb Mount Everest, meditating in a temple in India, or luxuriating on a Hawaiian beach, these vacations are what dreams are made of. So it's no

Form 8.3 - The Vanguard Group, Inc.: Horizon Therapeutics plc: https://mms.businesswire.com/media/20210505005534/en/876086/5/5009664_Horizon_Logo_Full-Color_CMYK_M01_%281%29.jpg
Form 8.3 - The Vanguard Group, Inc.: Horizon Therapeutics plc
Form 8.3 - The Vanguard Group, Inc.: Horizon Therapeutics plc
Form 8.3 - The Vanguard Group, Inc.: Horizon Therapeutics plc: https://mms.businesswire.com/media/20210505005534/en/876086/5/5009664_Horizon_Logo_Full-Color_CMYK_M01_%281%29.jpg
Form 8.3 - The Vanguard Group, Inc.: Horizon Therapeutics plc
Form 8.3 - The Vanguard Group, Inc.: Horizon Therapeutics plc
EQS-News: Evotec SE provides update on cyber attack: http://s3-eu-west-1.amazonaws.com/sharewise-dev/attachment/file/23749/Evotec_high_res_logo_%28blue_and_grey%29.jpg
EQS-News: Evotec SE provides update on cyber attack
EQS-News: Evotec SE provides update on cyber attack
EQS-Adhoc: Cyber Attack on Evotec: http://s3-eu-west-1.amazonaws.com/sharewise-dev/attachment/file/23749/Evotec_high_res_logo_%28blue_and_grey%29.jpg
EQS-Adhoc: Cyber Attack on Evotec
EQS-Adhoc: Cyber Attack on Evotec
Form 8.3 - The Vanguard Group, Inc.: Horizon Therapeutics plc: https://mms.businesswire.com/media/20210505005534/en/876086/5/5009664_Horizon_Logo_Full-Color_CMYK_M01_%281%29.jpg
Form 8.3 - The Vanguard Group, Inc.: Horizon Therapeutics plc
Form 8.3 - The Vanguard Group, Inc.: Horizon Therapeutics plc
Form 8.3 - The Vanguard Group, Inc.: Horizon Therapeutics plc: https://mms.businesswire.com/media/20210505005534/en/876086/5/5009664_Horizon_Logo_Full-Color_CMYK_M01_%281%29.jpg
Form 8.3 - The Vanguard Group, Inc.: Horizon Therapeutics plc
Form 8.3 - The Vanguard Group, Inc.: Horizon Therapeutics plc
CTS EVENTIM appoints Karsten Elbrecht as Chief Commercial Officer Ticketing Germany: http://s3-eu-west-1.amazonaws.com/sharewise-dev/attachment/file/23704/EVE_Logo.svg.png
CTS EVENTIM appoints Karsten Elbrecht as Chief Commercial Officer Ticketing Germany
CTS EVENTIM appoints Karsten Elbrecht as Chief Commercial Officer Ticketing Germany
EQS-News: AUTO1 Group SE: AUTO1 Group publishes 2022 ESG Report:
EQS-News: AUTO1 Group SE: AUTO1 Group publishes 2022 ESG Report
EQS-News: AUTO1 Group SE: AUTO1 Group publishes 2022 ESG Report
EQS-News: SHOP APOTHEKE EUROPE: VERY STRONG START TO YEAR, FASTEST GROWTH SINCE EARLY 2021.: https://upload.wikimedia.org/wikipedia/commons/thumb/0/07/Shop_Apotheke_Europe_logo.svg/640px-Shop_Apotheke_Europe_logo.svg.png
EQS-News: SHOP APOTHEKE EUROPE: VERY STRONG START TO YEAR, FASTEST GROWTH SINCE EARLY 2021.
EQS-News: SHOP APOTHEKE EUROPE: VERY STRONG START TO YEAR, FASTEST GROWTH SINCE EARLY 2021.
EQS-News: MorphoSys Completes Enrollment of Phase 3 MANIFEST-2 Study of Pelabresib in Myelofibrosis with Topline Results Expected by End of 2023: http://s3-eu-west-1.amazonaws.com/sharewise-dev/attachment/file/24061/Morphosys-logo.svg.png
EQS-News: MorphoSys Completes Enrollment of Phase 3 MANIFEST-2 Study of Pelabresib in Myelofibrosis with Topline Results Expected by End of 2023
EQS-News: MorphoSys Completes Enrollment of Phase 3 MANIFEST-2 Study of Pelabresib in Myelofibrosis with Topline Results Expected by End of 2023
EQS-News: MorphoSys Completes Enrollment of Phase 3 MANIFEST-2 Study of Pelabresib in Myelofibrosis with Topline Results Expected by End of 2023: http://s3-eu-west-1.amazonaws.com/sharewise-dev/attachment/file/24061/Morphosys-logo.svg.png
EQS-News: MorphoSys Completes Enrollment of Phase 3 MANIFEST-2 Study of Pelabresib in Myelofibrosis with Topline Results Expected by End of 2023
EQS-News: MorphoSys Completes Enrollment of Phase 3 MANIFEST-2 Study of Pelabresib in Myelofibrosis with Topline Results Expected by End of 2023
Form 8.3 - The Vanguard Group, Inc.: Horizon Therapeutics plc: https://mms.businesswire.com/media/20210505005534/en/876086/5/5009664_Horizon_Logo_Full-Color_CMYK_M01_%281%29.jpg
Form 8.3 - The Vanguard Group, Inc.: Horizon Therapeutics plc
Form 8.3 - The Vanguard Group, Inc.: Horizon Therapeutics plc
EQS-News: AUTO1 Group SE: Launch of the AUTO1 Group Price Index shows used car price stabilization after record decline:
EQS-News: AUTO1 Group SE: Launch of the AUTO1 Group Price Index shows used car price stabilization after record decline
EQS-News: AUTO1 Group SE: Launch of the AUTO1 Group Price Index shows used car price stabilization after record decline
Form 8.3 - The Vanguard Group, Inc.: Horizon Therapeutics plc: https://mms.businesswire.com/media/20210505005534/en/876086/5/5009664_Horizon_Logo_Full-Color_CMYK_M01_%281%29.jpg
Form 8.3 - The Vanguard Group, Inc.: Horizon Therapeutics plc
Form 8.3 - The Vanguard Group, Inc.: Horizon Therapeutics plc
Form 8.3 - The Vanguard Group, Inc.: Horizon Therapeutics plc: https://mms.businesswire.com/media/20210505005534/en/876086/5/5009664_Horizon_Logo_Full-Color_CMYK_M01_%281%29.jpg
Form 8.3 - The Vanguard Group, Inc.: Horizon Therapeutics plc
Form 8.3 - The Vanguard Group, Inc.: Horizon Therapeutics plc
EQS-News: Supervisory Board appoints Claudia Schmitt as CFO of Siltronic AG to succeed Rainer Irle: http://s3-eu-west-1.amazonaws.com/sharewise-dev/attachment/file/24068/Siltronic_Logo.svg.png
EQS-News: Supervisory Board appoints Claudia Schmitt as CFO of Siltronic AG to succeed Rainer Irle
EQS-News: Supervisory Board appoints Claudia Schmitt as CFO of Siltronic AG to succeed Rainer Irle
EQS-News: Supervisory Board appoints Claudia Schmitt as CFO of Siltronic AG to succeed Rainer Irle: http://s3-eu-west-1.amazonaws.com/sharewise-dev/attachment/file/24068/Siltronic_Logo.svg.png
EQS-News: Supervisory Board appoints Claudia Schmitt as CFO of Siltronic AG to succeed Rainer Irle
EQS-News: Supervisory Board appoints Claudia Schmitt as CFO of Siltronic AG to succeed Rainer Irle
Form 8.3 - The Vanguard Group, Inc.: Horizon Therapeutics plc: https://mms.businesswire.com/media/20210505005534/en/876086/5/5009664_Horizon_Logo_Full-Color_CMYK_M01_%281%29.jpg
Form 8.3 - The Vanguard Group, Inc.: Horizon Therapeutics plc
Form 8.3 - The Vanguard Group, Inc.: Horizon Therapeutics plc